2005 Fiscal Year Final Research Report Summary
Preservation and treatment system of living tissue and organ by the cell proliferation control.
Project/Area Number |
15300182
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Medical systems
|
Research Institution | KYOTO UNIVERSITY |
Principal Investigator |
GEN Shokyu Kyoto University, Institute for Frontier Medical Sciences, Associate Professor, 再生医科学研究所, 助教授 (90283655)
|
Co-Investigator(Kenkyū-buntansha) |
TSUTSUMI Sadami Kyoto University, Institute for Frontier Medical Sciences, Professor, 再生医科学研究所, 教授 (00028739)
WADA Hiromi Kyoto University, Graduate School of Medicine and Faculty of Medicine, Professor, 大学院・医学研究科, 教授 (90167205)
NAKAMURA Takashi Kyoto University, Graduate School of Medicine and Faculty of Medicine, Professor, 大学院・医学研究科, 教授 (10201675)
KOMEDA Masasi Kyoto University, Graduate School of Medicine and Faculty of Medicine, Professor, 大学院・医学研究科, 教授 (20303810)
TANAKA Kouichi Kyoto University, Graduate School of Medicine and Faculty of Medicine, Professor, 大学院・医学研究科, 教授 (20115877)
|
Project Period (FY) |
2003 – 2005
|
Keywords | EGCG / living tissue preservation / transplantation / cornea / islet / platelet / intimal hyperplasia / immunotolerance |
Research Abstract |
Cornea : Addition of 200ug/mL of EGCG could extend the preservation period of rabbit and human cornea. After 2 weeks preservation, the proliferation ability and morphology of epithelial cells and endothelial cells. Islet and skin : 30-120ug/mL of EGCG could retain the viability and insulin producing ability of islet after cryopreservation. It was confirmed that skin was preserved better with EGCG than control. Nerve : It was found that rat sciatic nerves preserved with EGCG were able to allograft and a rejection did not occur and retained the function. Effect of immunotolerance : It was found that the amount of IL-2 decreased from 100-200ug/mL of EGCG treated lymphocytes less than 1/3. Lymphocyte transplantation revealed the immuno-tolerance ability of EGCG. Inhibition of intimalhyperplasia : 0.1-1.0mg/mL of EGCG treatment of vein grafts is an effective method to prevent neointimal hyperplasia following coronary artery bypass grafting (CABG). Platelet : It was found that platelet functions were retained after 1 week preservation with 50-100ug/mL of EGCG.
|
Research Products
(34 results)